Metabolic & GLP-1Evidence B1 cited

VK2735

aka VK2735 · Viking GLP-1/GIP · Viking dual agonist

Dual GLP-1/GIP receptor agonist with injectable and oral formulations.

Sequence

Read this before quoting the sequence

Amino acid sequence has not been publicly disclosed by Viking Therapeutics. The company and the peer-reviewed phase 2 publication describe VK2735 only as 'a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors', developed in both once-weekly subcutaneous and once-daily oral tablet formulations. No structure, formula, CAS number or PubChem CID could be verified from any acceptable source.

Source ↗

Mechanism of action

Dual agonist of the GLP-1 and GIP receptors (subcutaneous and oral programmes) developed for obesity; combines both incretin pathways to suppress appetite and improve glucose handling.

What the evidence actually shows

Grade B

Phase 3 initiated 2025. Both SC and oral in development.

Regulatory status

Status

Investigational. Not approved anywhere.

Clinical stage

Phase 3. ClinicalTrials.gov lists two active phase 3 trials of subcutaneous VK2735: VANQUISH-1 (NCT07104500, enrolment 4500, obesity/overweight, active not recruiting) and VANQUISH-2 (NCT07104383, enrolment 1100, type 2 diabetes with obesity/overweight, active not recruiting), both once-weekly SC over 78 weeks with a 52-week extension; VANQUISH-2 tested 7.5, 12.5 and 17.5 mg versus placebo. The subcutaneous phase 2 VENTURE (NCT06068946) and the oral phase 2 VENTURE-Oral (NCT06828055) trials are completed.

WADA

Not named on the WADA 2026 Prohibited List; no GLP-1 or GIP receptor agonist appears on it.

Source ↗

Dosing — what backs each figure

VK2735 is an investigational GLP-1/GIP dual agonist with published phase 2 dosing - 2.5, 5, 10 and 15 mg subcutaneously once weekly (titrated) over 13 weeks in the VENTURE trial - and phase 3 arms at 7.5, 12.5 and 17.5 mg once weekly. It is not approved anywhere, so there is no established or labelled dose, only trial regimens.

ClinicalApproved labelling or a published human trial

2.5, 5.0, 10 or 15 mg subcutaneously once weekly for 13 weeks, with titration to the final dose
176 adults with BMI >=30, or >=27 with at least one weight-related comorbidity (diabetes excluded); phase 2 VENTURE, 20 US sites · subcutaneous
Bays HE et al., Obesity (Silver Spring) 2026;34(3):537-549 (NCT06068946) ↗
7.5 mg, 12.5 mg or 17.5 mg once weekly
Adults for weight management (VANQUISH, phase 3) and adults with type 2 diabetes (VANQUISH-2, phase 3); both active, not recruiting · subcutaneous
ClinicalTrials.gov NCT07104500 and NCT07104383 (arm descriptions state the mg doses) ↗
Oral VK2735 administered daily; six active dose levels, mg amounts not disclosed in the registry record
Adults for weight management; phase 2 VENTURE-Oral Dosing (completed) · oral
ClinicalTrials.gov NCT06828055 ↗

No established human dose

No approved label or completed human trial establishes a dosing regimen for this compound. Anything presented as a standard protocol for it — anywhere — is someone's convention rather than a finding.

Handling and storage

No compound-specific stability data exists

Investigational product with no approved label; storage conditions are not disclosed in the trial registrations or the phase 2 publication. No data. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.

→ Reconstitution walkthrough → Reconstitution calculator

Safety

References (1)

Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, Ji S, Stubbe S, Hedges P, Lian B (2026) Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study ↗
Obesity (Silver Spring)PMID 41508550DOI
Phase 2 VENTURE trial (NCT06068946, n=176): weekly subcutaneous VK2735 produced mean weight reduction of 9.1% (2.5 mg) to 14.7% (15 mg) at week 13 versus 1.7% with placebo; 93% of treated participants lost at least 5% of body weight. Adverse events were predominantly gastrointestinal.

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
sequence, molecularFormula, molecularWeight, casNumber, pubchemCid, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent

Research use only

This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Metabolic & GLP-1

5-Amino-1MQ

A small molecule researched for blocking NNMT enzyme to boost NAD+ levels and fat metabolism.

Amycretin

Dual amylin/GLP-1 receptor agonist from Novo Nordisk. Single molecule.

AOD-9604

A modified hGH fragment researched for targeted fat breakdown without altering blood sugar or IGF-1.